ADOCIA Presents Preclinical Data at ObesityWeek® 2026 Confirming the Potential of AdoXLong™ for Monthly Injections of Peptides

LYON, France–(BUSINESS WIRE)–Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of metabolic diseases including diabetes and obesity, today announces the presentation of preclinical data in poster format on its AdoXLong™ platform applied to semaglutide, AdoXL Sema, at ObesityWeek® 2026, taking place in Washington, USA, November 14-

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.